GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

GLYCO-IMMUNE CHECKPOINT INHIBITORS

The Need

Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.

Learn more

The Scientific Opportunity

Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.

Learn more

The Approach

Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint inhibitors to treat cancer patients.

Learn more

Twitter

@Palleon_Pharma
Our co-founders Jim Broderick, @CarolynBertozzi and Paul Crocker are visionaries. They are driven by science and sa… http://XkgDgzFoaJ

@Palleon_Pharma
Our friend, colleague and Palleon co-founder @CarolynBertozzi will be formally admitted as a fellow of the… http://KL7hn7KRSO

Visit us on Twitter

Our Founding Science

Hear from Dr. Carolyn Bertozzi on glycoscience, Glyco-Immune Checkpoints, and how Palleon is positioned to advance this unexplored area of immuno-oncology to benefit patients.

Learn more